A Phase II Randomized, Double -Blind, Placebo Controlled Study to Assess Safety, Tolerability and Effect on Tumor Size of MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)
Phase: PHASE2
Conditions: Pigmented Villonodular Synovitis, PVNS, Giant Cell Tumor of the Tendon Sheath, GCCTS, Tenosynovial Giant Cell Tumor Localized or Diffused Type, GCTS
Sponsor: Novartis Pharmaceuticals

Novartis Institutes for BioMedical Research
MCS110
Clinical Trial Protocol CMCS110X2201
A Phase II randomized, double-blind (Part A, B and C), 
placebo controlled (Part A and B only), study to assess 
safety, tolerability and efficacyof MCS110 on tumor size in 
patients with pigmented villonodular synovitis (PVNS)
Document type:
Amended Protocol Version
EUDRACT number:
2011-002951-32
Version number:
v07(incorporating Amendment 07)(Clean)
Development phase:
II
Release date:
03-Jul-2018
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis